Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells (Q33715925)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells (English)

1 reference

Europe PubMed Central

28 July 2017

author name string

Jason E Foley

1

1 reference

Europe PubMed Central

28 July 2017

Jacopo Mariotti

2

1 reference

Europe PubMed Central

28 July 2017

Kaitlyn Ryan

3

1 reference

Europe PubMed Central

28 July 2017

Michael Eckhaus

4

1 reference

Europe PubMed Central

28 July 2017

Daniel H Fowler

5

1 reference

Europe PubMed Central

28 July 2017

publication date

1 September 2008

1 reference

Europe PubMed Central

28 July 2017

Biology of Blood and Marrow Transplantation

1 reference

Europe PubMed Central

28 July 2017

14

1 reference

Europe PubMed Central

28 July 2017

959-972

1 reference

Europe PubMed Central

28 July 2017

9

1 reference

Europe PubMed Central

28 July 2017

Interleukin-10-secreting type 1 regulatory T cells in rodents and humans.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

14 July 2018

STAT3: a potential therapeutic target in dendritic cells for the induction of transplant tolerance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

14 July 2018

Shared biology of GVHD and GVT effects: potential methods of separation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

14 July 2018

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

14 July 2018

Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

14 July 2018

Interleukin 2 plays a central role in Th2 differentiation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

14 July 2018

Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

14 July 2018

Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

14 July 2018

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

14 July 2018

Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

14 July 2018

Modulation of graft-versus-tumor effects in a murine allogeneic bone marrow transplantation model by tumor-derived transforming growth factor-betaI.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

14 July 2018

Impaired interleukin 4 signaling in T helper type 1 cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

14 July 2018

High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

14 July 2018

Interleukin (IL) 4, in the absence of antigen stimulation, induces an anergy-like state in differentiated CD8+ TC1 cells: loss of IL-2 synthesis and autonomous proliferation but retention of cytotoxicity and synthesis of other cytokines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

14 July 2018

Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

14 July 2018

Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

14 July 2018

IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

30 October 2018

The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

30 October 2018

Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

30 October 2018

Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

30 October 2018

Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

30 October 2018

Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

30 October 2018

Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

30 October 2018

Critical role of interleukin-2 in the development of acute graft-versus-host disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

30 October 2018

Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835696

30 October 2018

Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relation of an Interleukin-10 Promoter Polymorphism to Graft-versus-Host Disease and Survival after Hematopoietic-Cell Transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amelioration of acute graft vs host disease due to minor histocompatibility antigens by in vivo administration of anti-interleukin 2 receptor antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-10 dose-dependent regulation of CD4+ and CD8+ T cell-mediated graft-versus-host disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of graft versus host disease by inactivation of host antigen-presenting cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IL-10-dependent suppression of experimental allergic encephalomyelitis by Th2-differentiated, anti-TCR redirected T lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL

1 reference

https://pubmed.ncbi.nlm.nih.gov/18721759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.BBMT.2008.06.007

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33715925&oldid=1945295569"